Immunology

Making immunotherapy safe for AML

Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal ...

Oncology & Cancer

New metabolic profile in patients with acute myeloid leukemia

An article published in the journal Nature Communications describes a specific metabolic adaptation in some patients with acute myeloid leukemia affected by tandem mutations in the FLT3 gene. The findings, which could shed ...

Oncology & Cancer

New method predicts childhood hyperdiploid B-ALL relapse risk

An international research team coordinated by Dr. Oscar Molina and Dr. Pablo Menéndez, from the Josep Carreras Leukaemia Research Institute, identifies chromosomal abnormalities associated with relapse in a frequent subset ...

page 1 from 8